Early treatment initiation is crucial for cardiovascular risk reduction; however, many patients do not reach LDL-C treatment goals. Inclisiran, a small interfering RNA targeting hepatic PCSK9 ...

为解决现有体外模型难以准确预测 GalNAc 偶联 siRNA 体内代谢的问题，研究人员以 Inclisiran 为模型，对比其在多种体外系统与大鼠体内的代谢情况。结果发现大鼠血清等可模拟体内血液代谢，多种体外模型可模拟肝脏代谢。这为研究 Inclisiran 及其他 GalNAc 偶联 siRNA ...

1.1 This document describes the funding and supply arrangements for inclisiran (Leqvio®) as an option in the lipid management pathway. These arrangements follow from the recommendations NICE set out ...

Objectives VICTORION-Spirit was a hybrid study designed to assess the feasibility of implementing inclisiran, a novel cholesterol-lowering treatment and behavioural support within primary care centres ...

However, a newer, lesser-known drug promises to dramatically lower LDL (low-density lipoprotein) cholesterol with just two doses a year. Inclisiran, an innovative medication that claims to change the ...

Introduction: Inclisiran is a small interfering RNA drug which inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Inclisiran was recently approved for the treatment of ...

In the V-MONO study, 350 patients were randomized to receive either inclisiran (n = 174), ezetimibe, (n = 89) or placebo (n = 87). It is the first trial to assess a small interfering RNA (siRNA ...

The earlier introduction of inclisiran significantly reduced low-density lipoprotein concentrations without affecting statin compliance in patients with atherosclerotic cardiovascular disease in the ...

Cholesterol lowering with a strategy using the short interfering RNA agent, inclisiran, earlier in the treatment pathway led to significantly better long-term low-density lipoprotein (LDL ...

For patients who could not achieve their LDL goal on statins alone, an inclisiran-first strategy lowered LDL more than usual care. The inclisiran-first strategy did not cause more statin ...

In recent years, medical advancements have led to the development of various cholesterol-lowering medications and one such breakthrough medication is Inclisiran. KEM Hospital in Mumbai is ...

In the pursuit of addressing this health concern, KEM Hospital in Mumbai is currently conducting trials for a promising new medicine called Inclisiran. This medication has shown highly positive ...